Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single center, randomized, parallel assignment, and double-blind placebo-controlled pilot study to characterize the intestinal microbiome in patients with severe Alcoholic Hepatitis (SAH) and evaluate the safety and the trends in improvement of diversity of intestinal microbiome following administration of lyophilized capsules containing microbiota suspension from well screened health donors. The study aims to enroll 50 patients with SAH who will be randomly assigned in 1:1 where 25 patients will be assigned to receive orally administered lyophilized PRIM-DJ2727 and Standard of Care (SOC) and the other 25 patients will be assigned to receive placebo and SOC for 4 weeks.
Sponsor: Prasun Kumar Jalal
You may qualify if…
- ✓ 1. Any gender; male or female; aged 18- 75 years old.
- ✓ 2. Severe alcoholic hepatitis defined as 2.1 Onset of jaundice within prior 8 weeks. 2.2 Ongoing alcohol consumption of \>40 g/day (3 drinks) in females or \>60 g/day (4 drinks) in males for 6 months or more, with less than 60 days of abstinence before the onset of jaundice. 2.3 Aspartate aminotransferase \>50, Aspartate aminotransferase/Alanine aminotransferase ratio \> 1.5, BUT both values \<400 IU/L.
- ✓ 2.4 Serum total bilirubin \>3.0 mg/dl. 2.5 MELD score \>15 and/or Maddrey DF score of ≥32.
You may not qualify if…
- ✕ 1. Non-alcoholic related liver diseases.
- ✕ 2. Patients with swallowing dysfunction at risk of aspiration.
- ✕ 3. Patients at risk for or with known anatomic or functional gastrointestinal (GI) obstruction or who have undergone major intra-abdominal surgery in the last year.
- ✕ 4. Patients who have undergone placement of a portosystemic shunt, infection of which may require prolonged antibiotics.
- ✕ 5. Patients with any congenital or acquired immunodeficiency (Other than liver disease)
- ✕ 6. Uncontrolled infections, sepsis, or GI bleeding.
- ✕ 7. Presence of cancer especially patients with skin cancer who is receiving or may receive systemic chemotherapy or immunotherapy during the study period.
- ✕ 8. Underlying disease that might be exacerbated by proposed treatments (e.g. HCV, HBV, HIV, TB).
Where it's recruiting
Houston
Source: ClinicalTrials.gov · NCT05006430 · last updated 2025-01-23